AMLX vs JNJ · $561.6M cap vs P/E 17, rev $49.37B
Amylyx Pharmaceuticals Inc (AMLX) versus Johnson & Johnson (JNJ) — a side-by-side from cached financials, not a winner call.
Amylyx Pharmaceuticals Inc (AMLX) is a biotechnology company listed on US.
Johnson & Johnson (JNJ) is a drug manufacturers - general company listed on US. It is led by Joaquin Duato.
Latest reported AMLX revenue for 2025-12-31 was $0. Net income was -$144.7M. Revenue was down 100.0% from 2024-12-31 to 2025-12-31. AMLX currently screens at market cap $561.6M.
Latest reported JNJ revenue for 2026-06-28 was $49.37B. Net income was $10.77B. JNJ currently screens at market cap $375.37B and trailing P/E 17.4.
AMLX currently screens at market cap $561.6M. JNJ currently screens at market cap $375.37B and trailing P/E 17.4.
Not investment advice. Open the AMLX and JNJ stock pages for the full models.
Not investment advice.